Sector: MedicalAVALON PHARMACEUTIC (NASDAQ: AVRX)
Headlines
- Avalon Pharmaceuticals Announces Special Meeting Date
Apr 28, 2009 04:49 PM | AVRX
- Avalon Pharmaceuticals Receives Audit Opinion Containing Going Concern Statement - Apr 7 2009 3:03PM
Apr 07, 2009 03:00 PM | AVRX
- Avalon Pharmaceuticals Receives Staff Determination Regarding Nasdaq Delisting
Mar 17, 2009 03:01 PM | AVRX
- Avalon Pharmaceuticals Receives Extension of Time to Comply with NASDAQ Deficiency Notice
Dec 22, 2008 04:23 PM | AVRX
- Avalon Pharmaceuticals Receives NASDAQ Deficiency Notice - Nov 25 2008 2:41PM
Nov 25, 2008 02:23 PM | AVRX
- Clinical Data, Inc. to Acquire Avalon Pharmaceuticals
Oct 28, 2008 08:44 AM | AVRX, CLDA
- Avalon Pharmaceuticals Receives Nasdaq Deficiency Notice - Sep 26 2008 4:30PM
Sep 26, 2008 04:17 PM | AVRX
- Avalon Pharmaceuticals Reports Second Quarter 2008 Results
Aug 13, 2008 10:06 AM | AVRX
- Avalon Pharmaceuticals Sets Second Quarter 2008 Conference Call Date
Aug 05, 2008 09:05 AM | AVRX
- Avalon Pharmaceuticals Nominates Lead Clinical Development Candidate in its Beta-catenin Pathway Inhibitor Program
Jun 26, 2008 08:04 AM | AVRX
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
AVRX
|
Compare to S&P
|
| YTD |
95.88 %
|
101.62 %
|
| 4 Weeks |
21.28 %
|
16.44 %
|
| 12 Weeks |
78.13 %
|
76.31 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 40.00 %
|
|
EPS Growth in Last Year: 30.00 %
|
|
Sales Growth in Last Quarter: -91.94 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
